Table 1.
Selected baseline characteristics of all randomized study participants, as previously published [10].
| Vitamin D Group (n = 100) | Placebo Group (n = 100) | |
|---|---|---|
| Females (%) | 46 | 48 |
| Age (years) | 60.5 ± 10.9 | 59.7 ± 11.4 |
| Body mass index (kg/m2) | 30.4 ± 4.4 | 30.4 ± 6.2 |
| Active smoker (%) | 19 | 14 |
| Previous MI (%) | 8 | 5 |
| Office systolic BP (mm Hg) | 143.7 ± 15.2 | 142.3 ± 15.4 |
| Office diastolic BP (mm Hg) | 87.1 ± 10.3 | 86.8 ± 10.8 |
| 24-hour systolic BP (mmHg) | 132.1 ± 8.4 | 131.7 ± 9.7 |
| 24-hour diastolic BP (mmHg) | 78.6 ± 7.5 | 77.8 ± 8.4 |
| NT-proBNP (pg/mL) | 69 (35–142) | 99 (51–169) |
| PRC (μU/mL) | 16.3 (10.1–39.0) | 16.1 (9.5–52.0) |
| PAC (ng/mL) | 15.4 (9.7–19.4) | 14.7 (10.6–19.9) |
| eGFR (mL/min/1.73m2) CKI-EPI | 80.0 ± 17.9 | 77.2 ± 17.9 |
| PWV (m/s) | 8.42 ± 1.90 | 8.28 ± 2.26 |
| 25(OH)D (ng/mL) | 22.0 ± 5.7 | 20.5 ± 5.7 |
| 25(OH)D < 20 ng/mL (n) | 33 | 42 |
| 25(OH)D < 16 ng/mL (n) | 18 | 27 |
| 25(OH)D < 12 ng/mL (n) | 6 | 8 |
| PTH (pg/mL) | 48.9 (40.0–61.7) | 51.6 (39.5–65.8) |
| Plasma calcium (mmol/L) | 2.37 ± 0.10 | 2.37 ± 0.11 |
| Antihypertensive drugs (n) | 2 (1–3) | 2 (1–3) |
| ACE-inhibitor (%) | 25 | 38 |
| AT II blocker (%) | 33 | 31 |
| Thiazide diuretic (%) | 39 | 45 |
| Beta-blocker (%) | 44 | 49 |
| Calcium channel blocker (%) | 27 | 25 |
Data are presented as means with standard deviation, medians with interquartile ranges, or percentages. Comparisons between the vitamin D and placebo groups were calculated with Student’s t-test or Chi-square test. MI—myocardial infarction; BP—blood pressure; NT-proBNP—N-terminal pro-B-type natriuretic peptide; PRC—plasma renin concentration; PAC—plasma aldosterone concentration; eGFR—estimated glomerular filtration rate; PWC—pulse wave velocity; 25(OH)D—25-hydroxyvitamin D; PTH—parathyroid hormone.